ACST Stock – (NASDAQ: ACST) is providing an update on the usage
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually giving an update on the use of the “at the market” equity of its providing program.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering system under which Acasti may well issue and market from time to time its common shares having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions found on January twenty seven, 2021, Acasti issued an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares were marketed at prevailing market costs averaging US$1.0747 a share. No securities had been marketed throughout the facilities of the TSXV or perhaps, to the knowledge of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a consequence of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and great as of March 5, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and often will provide the Company with more freedom in its ongoing review process to explore and evaluate strategic alternatives.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically concentrated on the research, development and commercialization of prescription medications using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have extensive clinical proof of efficacy as well as safety for lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for individuals with severe HTG.
Forward Looking Statements – ACST Stock
Statements in this press release which are not statements of historical or current truth constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking claims include known and unknown risks, uncertainties, along with other unknown variables that can result in the particular outcomes of Acasti to be materially different from historical outcomes and even as a result of any future results expressed or perhaps implied by such forward looking statements. In addition to statements which explicitly describe such risks and uncertainties, people are actually urged to look at statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other similar expressions to be forward-looking and uncertain. People are cautioned not to place undue reliance on these forward looking statements, which speak simply as of the particular date of this press release. Forward-looking assertions in this press release include, but aren’t limited to, information or statements about Acasti’s strategy, future operations and its review of strategic options.
The forward looking assertions found in this specific press release are expressly qualified in the entirety of theirs by this cautionary statement, the “Special Note Regarding Forward Looking Statements” section contained in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10 Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com as well as on the investor area of Acasti’s website at www.acastipharma.com. Many forward-looking statements in that press release are produced as of the date of this particular press release.
ACST Stock – Acasti does not undertake to redesign some such forward looking statements whether as a consequence of brand new info, future events or perhaps otherwise, except as needed by law. The forward-looking assertions contained herein are also subject generally to risks and assumptions and uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the use